Oprazole (Omeprazole)

Oprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders:

• Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis.
• Peptic ulcer disease: accelerates ulcer healing and reduces recurrence risk.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumours.
• Helicobacter pylori eradication regimens (as part of combination therapy): enhances eradication rates when used with antibiotics.

• Omeprazole irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly lowers gastric acidity, allowing mucosal healing and symptom relief in acid‑related conditions.

Adverse reactions to Oprazole may vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually self‑limiting.
• Nausea or vomiting: transient gastrointestinal discomfort.
• Abdominal pain or flatulence: mild abdominal upset.
• Constipation: occasional bowel habit change.
• Dry mouth: reduced salivary flow.

Serious or Rare Side Effects

• Clostridioides difficile‑associated colitis: severe diarrhoea with fever.
• Acute interstitial nephritis: renal inflammation presenting with reduced urine output.
• Hypomagnesemia: low serum magnesium causing muscle cramps or arrhythmia.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.
• Fracture risk: increased incidence of hip, wrist or vertebral fractures with long‑term use.

When prescribing Oprazole, clinicians should consider several safety aspects:

• Assess renal and hepatic function: dose adjustment may be required in severe impairment.
• Evaluate for Helicobacter pylori infection: testing and eradication may be needed.
• Review concomitant medications: potential for altered absorption of drugs requiring acidic pH.
• Monitor long‑term users: watch for bone density loss and magnesium levels.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Oprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk.
• Atazanavir or other protease inhibitors: markedly decreased antiviral exposure.
• Methotrexate (high dose): increased serum concentrations, risk of toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: possible alteration of INR, requiring more frequent monitoring.
• Digoxin: modest increase in serum levels.
• Phenytoin: reduced plasma concentration, may diminish seizure control.